Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant
Open Access
- 7 October 2019
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 39 (5) , 987-1003
Abstract
Despite intense research and clinical efforts, patients affected by advanced colorectal cancer (CRC) have still a poor prognosis. The discovery of colorectal (CR) cancer stem cell (CSC) as the cell compartment responsible for tumor initiation and propagation may provide new opportunities for the development of new therapeutic strategies. Given the reduced sensitivity of CR-CSCs to chemotherapy and the ability of bone morphogenetic proteins (BMP) to promote colonic stem cell differentiation, we aimed to investigate whether an enhanced variant of BMP7 (BMP7v) could sensitize to chemotherapy-resistant CRC cells and tumors. Thirty-five primary human cultures enriched in CR-CSCs, including four from chemoresistant metastatic lesions, were used for in vitro studies and to generate CR-CSC-based mouse avatars to evaluate tumor growth and progression upon treatment with BMP7v alone or in combination with standard therapy or PI3K inhibitors. BMP7v treatment promotes CR-CSC differentiation and recapitulates the cell differentiation-related gene expression profile by suppressing Wnt pathway activity and reducing mesenchymal traits and survival of CR-CSCs. Moreover, in CR-CSC-based mouse avatars, BMP7v exerts an antiangiogenic effect and sensitizes tumor cells to standard chemotherapy regardless of the mutational, MSI, and CMS profiles. Of note, tumor harboring PIK3CA mutations were affected to a lower extent by the combination of BMP7v and chemotherapy. However, the addition of a PI3K inhibitor to the BMP7v-based combination potentiates PIK3CA-mutant tumor drug response and reduces the metastatic lesion size. These data suggest that BMP7v treatment may represent a useful antiangiogenic and prodifferentiation agent, which renders CSCs sensitive to both standard and targeted therapies.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (5x1000 (9979), 5x1000 (9979))
This publication has 52 references indexed in Scilit:
- Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in boneJournal of Experimental Medicine, 2011
- Juvenile polyposis syndromeWorld Journal of Gastroenterology, 2011
- Bone morphogenetic protein receptors and signal transductionThe Journal of Biochemistry, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- TGFβ in CancerCell, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factorsProceedings of the National Academy of Sciences, 2007
- Authors’ replyGut, 2006
- Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferationProceedings of the National Academy of Sciences, 2006
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003